Brief: Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment
22/02/2024 14:46
Feb 22 (Reuters) - Notable Labs Ltd NTBL.O :
* NOTABLE ADVANCES VOLASERTIB PHASE 2 PROGRAM UTILIZING
PROPRIETARY PREDICTIVE PRECISION MEDICINE PLATFORM-GUIDED
ENROLLMENT
* NOTABLE LABS LTD - VOLASERTIB PHASE 2 TRIAL INITIATION IN
RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA ANTICIPATED IN Q2
2024, AND FIRST DATA IN Q4 2024
Source text for Eikon: ID:nGNX5hwQ3R
Further company coverage: NTBL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives